Drug Development

Additional indication of anemia in premature infants approved for Epogin

Published in Drug Week, June 9th, 2006

Chugai Pharmaceutical Co., Ltd., announced that the recombinant human erythropoietin Epogin (epoetin beta - recombinant), currently marketed for indication of renal anemia and predeposit of red blood cell transfusion, had obtained an additional effect-efficacy for anemia in premature infants on April 20, 2006.

For Epogin Injection Ampoule 750, 1500, and 3000, Chugai filed submission for additional indication in March 2002 (for Epogin Injection Syringe 750, 1500, and 3000, November 2005), which led to the approval of additional indication and administration-dosage this time.

"Anemia in premature infants" is a type of anemia frequently found in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry